A Phase I Randomized, Dose Escalation Study of the Safety and Efficacy of Intracoronary Delivery of Cardiosphere-Derived Stem Cells in Patients With Ischemic Left Ventricular Dysfunction and a Recent Myocardial Infarction
Latest Information Update: 31 May 2019
At a glance
- Drugs Autologous stem cell therapy (Primary)
- Indications Myocardial infarction; Ventricular dysfunction
- Focus Adverse reactions
- Acronyms CADUCEUS
- 23 Dec 2013 New trial record